Daclizumab HYP efficacy on disease outcome measures using an expanded definition of highly active relapsingremitting multiple sclerosis: Results from SELECT and DECIDE

Authors
Category Primary study
ConferenceEuropean Journal of Neurology
Year 2016
This article has no abstract
Epistemonikos ID: 471d9a34c1d9adf7bb79223de3c381f1710b17c3
First added on: Apr 30, 2026